Clinical trials: Fatty Liver, Alcoholic
Non-alcoholic Fatty Liver Disease (NAFLD)
Association of Non-alcoholic Fatty Liver Disease and Diabetes Mellitus
This study will evaluate the association of non-alcoholic fatty liver disease and diabetes mellitus. Patients presenting in our clinic with Diabetes mellitus type 1 or 2 will receive the following examination: Transient…
- Trial name
- NCT01997424
- Testing
- Controlled Attenuation Parameter (CAP), Echosens, Paris, France, FibroScan, Echosens, Paris, France
- Where
- Germany
- Volunteers
- 340 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH)
Longitudinal Observational Study Of Chinese With NAFLD/NASH
This is a 10-year, longitudinal, observational study of patients with NAFLD/NASH designed to specifically address important clinical questions that remain incompletely answered from registration trials.
- Trial name
- NCT03151473
- Where
- Hong Kong
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Humanity and Health Research Centre
Obese
Changes in Intrahepatic Lipids With Exercise
Individuals with obesity and particular type 2 diabetes have abnormally high levels of fat in liver cells and are at increased risk for cardiovascular and liver-related mortality.
- Trial name
- NCT02181270
- Testing
- high intensity exercise, continuous moderate exercise
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
Non-alcoholic Fatty Liver Disease, Morbid Obesity
Ursodeoxycholic Acid in Bariatric Surgery
In an open-label trial, 20 otherwise healthy morbidly obese patients scheduled for bariatric surgery will be administered 20 mg/kg/day ursodeoxycholic acid for three weeks until the day before surgery.
- Trial name
- NCT01548079
- Testing
- Ursodeoxycholic Acid (UDCA)
- Volunteers
- 40 people
- Sponsor
- Sahlgrenska University Hospital
NASH
A Multicenter, Double-blind, Placebo-randomized Controlled Clinical Study on the Treatment of Non-alcoholic Steatohepatitis With Tibetan Drug Langqing Atar
non-alcoholic steatohepatitis (NASH) is an inflammatory liver disease caused by the accumulation of fat in liver cells. With the change of living habits and diet, the incidence of Nash continues to increase.
- Trial name
- NCT06193629
- Testing
- Lang Qingata
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Shupei Li
Nonalcoholic Steatohepatitis (NASH)
Comparing the Effects of Vitamin E, Ursodeoxycholic Acid and Pentoxyfylline on Egyptian Non-alcoholic Steatohepatitis (NASH) Patients
We conducted a 3-month, randomized, single-blind study in 102 Egyptian NASH patients who were divided into three groups; group 1 included 34 patients received Vit.
- Trial name
- NCT04977661
- Testing
- Vitamin E, Ursodeoxycholic acid, Pentoxifylline
- Where
- Egypt
- Volunteers
- 102 people
- Sponsor
- Kafrelsheikh University
Type 2 Diabetes, Nonalcoholic Fatty Liver Disease
Hepatic Dysfunction, Vitamin D Status, and Glycemic Control in Diabetes
This study is designed to study the effect of vitamin D intake on the severity of fatty liver and poor glucose control in patients with type 2 diabetes and fatty liver disease.
- Conditions
- Type 2 Diabetes, Nonalcoholic Fatty Liver Disease, Vitamin D Deficiency
- Trial name
- VDLS (NCT02132442)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Massachusetts, Worcester
Non-Alcoholic Fatty Liver
Study to Evaluate the Effect of Elafibranor on Hepatic Lipid Composition in Subjects With Nonalcoholic Fatty Liver (NAFL)
This randomized, double-blind, cross-over (placebo or elafibranor [GFT505]) placebo-controlled study, will evaluate the effect on hepatic lipid composition and safety of elafibranor 120 mg quaque die (QD) versus placebo in an…
- Trial name
- NCT03953456
- Testing
- elafibranor 120mg
- Where
- Netherlands
- Volunteers
- 17 people
- Sponsor
- Genfit
NAFLD, Alcohol-Related Disorder
Screening in Primary Care of Advanced Liver Fibrosis in NAFLD and/or Alcoholic Patients (IMPROVE Study)
The main objective is to determine the performance of the simple eLIFT blood test for advanced liver fibrosis screening in NAFLD and/or alcoholic patients in primary care.
- Conditions
- NAFLD, Alcohol-Related Disorder, Liver Fibrosis
- Trial name
- IMPROVE (NCT04146636)
- Testing
- e-LIFT
- Where
- France
- Volunteers
- 282 people
- Sponsor
- University Hospital, Angers
Type2 Diabetes Mellitus, Microangiopathy
"Preventing Cardiovascular Ischemic Events and Arresting Their Consequences in Type 2 Diabetic Population
Current methods based on traditional Cardiovascular risk factors are not clinically useful for identifying Type 2 Diabetes patients at risk of developing acute Cardiovascular ischemic events (ie.myocardial infarction or stroke).
- Conditions
- Type2 Diabetes Mellitus, Microangiopathy, Non Alcoholic Fatty Liver Disease, Coronary Artery Disease
- Trial name
- PRECISED (NCT02248311)
- Where
- Spain
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Non-Alcoholic Fatty Liver Disease
A Study of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease.
- Trial name
- NCT03350165
- Testing
- K-877
- Where
- 16 sites in Japan
- Volunteers
- 118 people
- Sponsor
- Kowa Company, Ltd.
Non-Alcoholic Steatohepatitis (NASH)
IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)
Purpose of this study is to assess the effects of pemvidutide on NASH resolution and NASH fibrosis.
- Trial name
- IMPACT (NCT05989711)
- Testing
- Pemvidutide
- Where
- 40 sites in United States, Australia and 1 more
- Volunteers
- 212 people
- Sponsor
- Altimmune, Inc.
Cirrhosis
Breath Test to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Cirrhotics
The three objectives of this trial are: 1. To demonstrate that a decline in hepatic metabolic function as measured by BreathID will correlate with changes in CTP and MELD scores in patients with cirrhosis. 2.
- Trial name
- NCT00375011
- Where
- 3 sites in United States, Israel
- Volunteers
- 200 people
- Sponsor
- Meridian Bioscience, Inc.
Non-Alcoholic Fatty Liver Disease, Obesity
Multicenter, Randomized, Controlled and Double-blind Study of Efficacy and Safety of Endoscopic Gastric Tubulization in Patients With Non-alcoholic Steatohepatitis (NASH-APOLLO).
Nonalcoholic steatohepatitis is a growing public health problem affecting over 5% of the population. These patients are at increased risk of cardiovascular and liver-related death and have higher rates of malignancy.
- Trial name
- NASH-APOLLO (NCT03426111)
- Testing
- Endoscopic Gastric Tubulization with OverStitch® system (Apollo Endosurgery, Austin, TX, USA), Lifestyle modification
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Puerta de Hierro University Hospital
Non Alcoholic Steatohepatitis (NASH)
Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis
This study will compare the effects of AXA1125, an orally active mixture of amino acids, compared to placebo, on improving fat and inflammation (steatohepatitis) as well as fibrosis in subjects with non alcoholic steatohepatitis…
- Trial name
- NCT04880187
- Testing
- AXA1125
- Where
- 75 sites in United States, Australia and 5 more
- Volunteers
- 273 people
- Sponsor
- Axcella Health, Inc
Non Alcholic Fatty Liver Disease
Efficacy and Safety of Picroliv in Patients With Non-Alcoholic Fatty Liver Disease
This is a Phase III, multicentre, randomized, double-blind, placebo-controlled, interventional study designed to evaluate the efficacy and safety of a standardized fraction of Picrorhiza kurroa Royal Ex Benth (Picroliv®) in…
- Trial name
- NCT07452744
- Testing
- Picroliv
- Where
- 6 sites in India
- Volunteers
- 170 people
- Sponsor
- Bioagile Therapeutics Pvt. Ltd.
NASH, NAFLD
Digoxin In NASH (CODIN)
Nonalcoholic steatohepatitis (NASH) is a severe subtype of nonalcoholic fatty liver disease (NAFLD) which affects 1 in 3 Americans.
- Conditions
- NASH, NAFLD, MASH - Metabolic Dysfunction-Associated Steatohepatitis, Mash
- Trial name
- CODIN (NCT06588699)
- Testing
- Digoxin
- Where
- 2 sites in United States
- Volunteers
- 144 people
- Sponsor
- Yale University
Non-Alcoholic Fatty Liver Disease
The Clock Thickens: Morning or Evening Training for the Treatment of NAFLD?
The goal of this clinical trial is to investigate the different effect of morning and evening exercise training in individuals with non-alcoholic fatty liver disease (NAFLD).
- Trial name
- TikTac (NCT05987748)
- Testing
- Exercise training
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- Leiden University Medical Center
Effects of Bacillus Coagulans TCI711 Supplementation on Liver and Gut Microbiota Function in Non-alcoholic Fatty Liver Disease Patients
Effects of Bacillus Coagulans on Liver and Gut Microbiota Function in NAFLD
According to the 2018 statistics of the American Association of Liver Diseases, about 25% of the world's population has non-alcoholic fatty liver disease, and about 10 to 20% of patients with simple fatty liver will develop…
- Trial name
- NCT05635474
- Testing
- Bacillus Coagulans
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Taipei Medical University
Non-alcoholic Fatty Liver Disease (NAFLD)
Exercise Dose and Nonalcoholic Fatty Liver Disease
The purpose of this research is to provide a better understanding of how exercise (walking) affects non-alcoholic fatty liver disease (NAFLD) in overweight people.
- Trial name
- ED (NCT00771108)
- Testing
- exercise
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine